mRNA-1345 is an mRNA vaccine encoding a pre-fusion RSV F-glycoprotein for the prevention of lower respiratory tract infection caused by RSV. mRNA-1345 is a nucleoside modified mRNA encoding the F-glycoprotein from RSV subtype A stabilized in its prefusion conformation.
- Mechanism
- Curator reviewed · 2 references
mRNA-1345 (mRESVIA) is an mRNA-based vaccine encoding the F glycoprotein from RSV subtype A stabilized in the prefusion conformation (pre-F protein). mRESVIA stimulates production of both RSV-A and RSV-B neutralising antibodies due to antigenic cross-reactivity between subtypes. It induces antigen-specific cellular immune responses that protect against RSV-associated respiratory tract disease.
- Primary indication
- In the US, mRESVIA is indicated for active immunization to prevent lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in patients ≥60 years of age and in patients 18 through 59 years...Curator reviewed · 3 structured indications
- First approval
- United States, 2024
- Also known as
- mRESVIA · Respiratory syncytial virus pre-fusion glycoprotein F mRNA
- Code names
- CX-032753 · mRNA-1345 · RNA-100-AR02
- Brand names
Resolves to
What you can answer from here — as of June 03, 2026
Which other approved drugs treat the same conditions as mRNA-1345, and which companies have late-stage candidates in those indications?
Create a free account or log in to explore the full data card.
Create Account